KIT and gastrointestinal stromal tumor: Compound 75 showed excellent growth inhibition in all KIT-mutant Ba/F3 cell lines and PDGFR-driven cell lines relevant to the subsets of GISTs, including the clinically GIST-relevant D842V mutant compared with clinically approved and unapproved KIT inhibitors.